Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024
Continued preparations to launch LV portfolio.
Agreement reached with FDA on Phase 2 pivotal study design of RP-L301 for PKD to support accelerated approval; Initiating single-arm, 10-patient pivotal study with primary endpoint of ≥1.5 point Hgb improvement at 12 monthsInitiated Phase 2 pivotal trial of RP-A501 for Danon Disease following FDA alignmentInitiated.
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.